Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases
22. November 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay
Liquid Biopsy Market Size to Worth USD 28.84 Billion by 2033 | Straits Research
21. November 2024 09:55 ET
|
Straits Research Private Limited - Garner Insights
New York, United States, Nov. 21, 2024 (GLOBE NEWSWIRE) -- "Liquid biopsy" isolates and detects circulating nucleic acids (DNA or RNA), exosomes, and circulating tumor cells to diagnose primary...
Metastatic Triple-Negative Breast Cancer (mTNBC) Pipeline Landscape Research 2024: Comprehensive Insights About 10+ Companies and 12+ Drugs
21. November 2024 04:05 ET
|
Research and Markets
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Triple-Negative Breast Cancer (mTNBC)- Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This...
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium
20. November 2024 08:30 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas...
Organic Remedies Donates $20,000 to Support Pennsylvania Breast Cancer Survivors and Their Families
20. November 2024 07:15 ET
|
Organic Remedies
Organic Remedies, a medical marijuana organization, raised $20,000 to support the PA Breast Cancer Coalition through patient donations and product sales.
AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer
19. November 2024 08:00 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data were published on Roswell Park Comprehensive Cancer...
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
12. November 2024 16:01 ET
|
Olema Oncology
Presented compelling new preclinical data demonstrating anti-tumor activity for OP-3136, a novel KAT6 inhibitor, with enhanced activity of palazestrant combinations at EORTC-NCI-AACR Symposium on...
WAKE RADIOLOGY CELEBRATES SUCCESS OF BREAST CANCER AWARENESS MONTH CAMPAIGN
12. November 2024 09:15 ET
|
Wake Radiology UNC Health Rex
Raleigh, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Wake Radiology just completed its “We See the Difference” breast cancer awareness campaign, designed to support the goals of National Breast Cancer...
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
12. November 2024 08:30 ET
|
Atossa Therapeutics, Inc.
Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key...
Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call
07. November 2024 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...